Pharmacare successfully helped its partner Boan Biotech obtain the GMP certificate from the Brazilian National Health Supervision Bureau

Pharmacare successfully helped its partner Boan Biotech obtain the GMP certificate from the Brazilian National Health Supervision Bureau

Congratulations to our partner Boan Biotech for recently receiving the GMP certificate awarded by the Brazilian National Health Supervision Agency (ANVISA), covering its biopharmaceutical product Boyonuo® (bevacizumab injection) dope and injection. Pharmacare participated in and led the product's registration application and GMP certification application throughout the entire process, and helped Boan Biotech successfully obtain the ANVISA GMP certificate with the fastest, all-round and most professional services.

About the Brazilian pharmaceutical market

Brazil is a member of PIC/S and one of the world's major emerging pharmaceutical markets with a vast market space. IQVIA data shows that the Brazilian pharmaceutical market will be approximately US$30.2 billion in 2022, accounting for about half of the entire Latin American pharmaceutical market, and is expected to maintain an annual growth rate of 7-10% from 2023 to 2027. From the perspective of local patient needs, data released by the World Health Organization's International Agency for Research on Cancer show that breast cancer, lung cancer, colorectal cancer, and cervical cancer ranked among the top ten new cancer incidence rates in Brazil in 2020, and there are a large number of unmet treatments. need. Bevacizumab, as the preferred drug for anti-angiogenesis therapy, plays an important role in the treatment of various malignant tumors, including the above-mentioned cancer types. The entry of Boyono® into the Brazilian market can further improve the accessibility of medicines to local patients and prolong their high-quality survival time.

Introduction to Pharmacare 

Pharmacare is committed to China's pharmaceutical exports to emerging markets and regulatory markets. Pharmacare is the first company to register and list Chinese generic drugs in Brazil. It is the largest exporter of pharmaceutical preparation products from China to Brazil. It has ranked first in China's blood product export industry for four consecutive years. It has established a joint venture in Brazil in 2023. Opening a new chapter in the localized operation of Pharmacare's target market.

Farmer has built a comprehensive business platform from intermediates to APIs to preparations, which is not limited to providing commercial solutions, clinical solutions, registration solutions, technical solutions, etc., such as quality standard upgrades, CTD file compilation, introduction of advanced technology, etc. Through years of experience accumulation and capability resource accumulation in the field of internationalization of pharmaceutical products, Pharmacare has created a 7-in-1 comprehensive service platform for the international sales of Chinese pharmaceutical products, building the differentiated core competitiveness of the company.

Pharmacare adheres to the business cooperation concept of "integrating resources, complementing advantages, and empowering partners" to sustainably create value for partners and jointly expand and strengthen the international and domestic markets.

About Boan Biotechnology

Boan Biotech (6955.HK) is a comprehensive biopharmaceutical company specializing in the development, production and commercialization of biopharmaceuticals, focusing on tumors, autoimmunity, ophthalmology and metabolic diseases.

Currently, Boan Biotech has two commercialized products, as well as multiple product portfolios under development of innovative biopharmaceuticals and biosimilars with international intellectual property protection.

In addition to China, Boan Biotech is also engaged in the development of biopharmaceutical products in overseas markets, including Europe and the United States.